NYXH Nyxoah SA
Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat obstructive sleep apnea. Its lead solution is the Genio system, a hypoglossal neurostimulations therapy for obstructive sleep apnea. The company was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.…
Industry Peers
Medical DevicesKey Statistics
About Nyxoah (EBR: NYXH)
›
Nyxoah (EBR: NYXH) is listed on Euronext Brussels, where its shares trade in EUR. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 153 employees.
The shares were at 0.7480 EUR on 20 November 2026, down 81.6% over 52 weeks. Its 52-week range is 0.6970 EUR to 4.735 EUR: the price is 84.2% below the high and 7.3% above the low.
Its market capitalisation is 76.18M EUR.
Nyxoah reports return on equity of -183.4%, an operating margin of -282.5% and revenue up 365.0% year over year.
It holds more cash than debt, a net cash position of 23.22M EUR. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health. The next earnings report is expected on 18 March 2027.